References

Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Children Younger Than 5 Years in 2019: A Systematic Analysis

10.1016/s0140-6736(22)00478-0 · 2022 · External reference

Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: a Systematic Review and Modelling Study

10.1016/s0140-6736(17)30938-8 · 2017 · External reference

Respiratory Syncytial Virus is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample

10.1093/infdis/jiac120 · 2022 · External reference

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High‐Risk Infants

10.1542/peds.102.3.531 · 1998 · External reference

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

10.1542/peds.2014-1665 · 2014 · External reference

Cost‐Effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review

10.1542/peds.2018-4064 · 2019 · External reference

Single‐Dose Nirsevimab for Prevention of RSV in Preterm Infants

10.1056/nejmoa1913556 · 2020 · External reference

Nirsevimab for Prevention of RSV in Healthy Late‐Preterm and Term Infants

10.1056/nejmoa2110275 · 2022 · External reference

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

10.1056/nejmoa2309189 · 2023 · External reference

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

10.1056/nejmoa2216480 · 2023 · External reference

Clesrovimab for Prevention of RSV Disease in Healthy Infants

10.1056/nejmoa2502984 · 2025 · External reference

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023

10.15585/mmwr.mm7234a4 · 2023 · External reference

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus‐Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023

10.15585/mmwr.mm7241e1 · 2023 · External reference

Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus‐Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025

10.15585/mmwr.mm7432a3 · 2025 · External reference

WHO Position Paper on Immunization to Protect Infants Against Respiratory Syncytial Virus Disease, May 2025

2025 · External reference

Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination—United States, October 2023–March 2024

10.15585/mmwr.mm7431a3 · 2025 · External reference

Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months—United States, April 2024

10.15585/mmwr.mm7338a2 · 2024 · External reference

Cost of Childhood RSV Management and Cost‐Effectiveness of RSV Interventions: A Systematic Review from a Low‐ and Middle‐Income Country Perspective

10.1186/s12916-023-02792-z · 2023 · External reference

Prevention of Respiratory Syncytial Virus From 1991 to 2024: A Systematic Review and Bibliometrics Analysis

10.21037/tp-24-271 · 2024 · External reference

Research Hotspots and Global Trends in Respiratory Syncytial Virus over Past Five Years

10.3389/fmicb.2025.1599093 · 2025 · External reference

Evidence & Gap Maps: A Tool for Promoting Evidence Informed Policy and Strategic Research Agendas

10.1016/j.jclinepi.2016.05.015 · 2016 · External reference

Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping

10.1007/s11192-009-0146-3 · 2010 · External reference

A Coefficient of Agreement for Nominal Scales

10.1177/001316446002000104 · 1960 · External reference

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus‐Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season—New Vaccine Surveillance Network, October 2023–February 2024

10.15585/mmwr.mm7309a4 · 2024 · External reference

Nirsevimab and Hospitalization for RSV Bronchiolitis

10.1056/nejmoa2314885 · 2024 · External reference

Nirsevimab Effectiveness at Preventing RSV‐Related Hospitalization in Infants

10.1056/evidoa2400275 · 2025 · External reference

Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024

10.1001/jamanetworkopen.2024.53696 · 2025 · External reference

Effectiveness of Nirsevimab Immunisation After Birth Versus RSVpreF Maternal Vaccination in Preventing RSV‐Related Hospitalisations in Infants: A Population‐Based Retrospective Cohort Study

10.1016/s2352-4642(26)00075-1 · 2026 · External reference

Nirsevimab Vs RSVpreF Vaccine for Respiratory Syncytial Virus‐Related Hospitalization in Newborns

10.1001/jama.2025.24082 · 2026 · External reference

Impact of Universal Nirsevimab Prophylaxis in Infants on Hospital and Primary Care Outcomes Across Two Respiratory Syncytial Virus Seasons in Galicia, Spain (NIRSE‐GAL): A Population‐Based Prospective Observational Study

10.1016/s1473-3099(25)00742-x · 2026 · External reference

The Evolving Landscape of RSV Immunization: Current Policies and Practices Across Europe

10.1016/j.vaccine.2026.128222 · 2026 · External reference

Cost‐Effectiveness of Pharmaceutical Strategies to Prevent Respiratory Syncytial Virus Disease in Young Children: A Decision‐Support Model for Use in Low‐Income and Middle‐Income Countries

10.1186/s12916-023-02827-5 · 2023 · External reference

Cost‐Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children

10.1542/peds.2024-066461 · 2024 · External reference

Cost‐Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness

10.1542/peds.2024-066481 · 2024 · External reference

Cost‐Effectiveness of Nirsevimab and Maternal RSVpreF for Preventing Respiratory Syncytial Virus Disease in Infants Across Canada

10.1186/s12916-025-03928-z · 2025 · External reference

Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes

10.1001/jamanetworkopen.2024.19268 · 2024 · External reference

Unresolved reference

External reference